0001209191-24-000902.txt : 20240104
0001209191-24-000902.hdr.sgml : 20240104
20240104190443
ACCESSION NUMBER: 0001209191-24-000902
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novack David F
CENTRAL INDEX KEY: 0001573072
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34207
FILM NUMBER: 24513926
MAIL ADDRESS:
STREET 1: 39 YORKSHIRE DR
CITY: OAKLAND
STATE: CA
ZIP: 94618
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DYNAVAX TECHNOLOGIES CORP
CENTRAL INDEX KEY: 0001029142
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330728374
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2100 POWELL STREET
STREET 2: SUITE 720
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 5108485100
MAIL ADDRESS:
STREET 1: 2100 POWELL STREET
STREET 2: SUITE 720
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-02
0
0001029142
DYNAVAX TECHNOLOGIES CORP
DVAX
0001573072
Novack David F
C/O DYNAVAX TECHNOLOGIES
2100 POWELL STREET, SUITE 720
EMERYVILLE
CA
94608
0
1
0
0
President & COO
1
Common Stock
2024-01-02
4
M
0
9000
5.42
A
12187
D
Common Stock
2024-01-02
4
S
0
9000
14.45
D
3187
D
Stock Option (Right to Buy)
5.42
2024-01-02
4
M
0
9000
D
2027-02-11
Common Stock
9000
0
D
The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on May 5, 2023.
This transaction was executed in multiple trades at prices ranging from $13.98 to $14.53; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, Dynavax, or a security holder of Dynavax.
This option grant will vest over three (3) years with one third (1/3) of the shares subject to the option vesting twelve months after the grant date of February 12, 2020, and one thirty-sixth (1/36) of the shares subject to the option vesting on the last day of each month thereafter.
Not applicable.
/s/ David Novack
2024-01-04